Hints and tips:
...Of the large-cap health stocks, Vermeer Partners, another London-based wealth manager, favours medical device stocks Zimmer Biomet and Smith & Nephew, given that demand for elective surgery has been deferred...
...Smith & Nephew edged 0.4 per cent higher to £11.15 after US regulators set out terms for the purchase of Biomet by US peer Zimmer....
...Zimmer’s purchase of Biomet shows hospital purchasing decisions are increasingly focused on value rather than product features, which favours companies offering economies of scale, said Goldman....
International Edition